European Commission Consults on Pharmacovigilance - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

European Commission Consults on Pharmacovigilance


ePT--the Electronic Newsletter of Pharmaceutical Technology

The European Commission has released a concept paper for public consultation that provides details about implementing pharmacovigilance measures, which will be necessary as part of the Commission’s 2010 amended pharmacovigilance legislation.

The concept paper details several topics including:

  • pharmacovigilance system master files
  • the quality system for the performance of pharmacovigilance activities
  • the use of internationally agreed terminology, formats, and standards
  • monitoring data in the EudraVigilance database
  • the electronic transmission of suspected adverse reactions
  • electronic periodic safety update reports and risk-management plans
  • postauthorization safety studies.

According to the concept paper, these measures will supplement essential aspects of the new pharmacovigilance system with the more technical details that must be observed by marketing authorization holders, national competent authorities, and EMA in the daily practice of applying the new legislation. “It is therefore important that they are fit for purpose and strike the necessary balance between the fundamental objective of the current legislative framework for medicinal products, i.e. to safeguard public health, and general internal market requirements,” explains the concept paper.

The new legislation was formalized last year (Directive 2010/84/EU amending Directive 2001/83/EC, and Regulation (EU) No. 1235/2010 amending Regulation (EC) No 726/2004). According to an implementation plan, most of the provisions will come into force by the end of July 2012.

“This new public health legislation is far reaching in scope and in depth and goes far beyond any narrow concept of pharmacovigilance,” said the EMA in the implementations plan. “The legislation strengthens safety monitoring, [rationalizes] reporting and increases the use of studies including pharmacoepidemiology, makes clear roles and responsibilities, sets out decision-making, increases participation, reinforces transparency and strengthens the action that can be taken to protect and promote public health.”

The paper describes the scope and content of the implementing measures and will be available for consultation until Nov. 7, 2011. The Commission is seeking the views of all stakeholders, and details on how to participate are available on the EMA website.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerTargeting Different Off-Shore Destinations
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAsymmetric Synthesis Continues to Advance
Jill Wechsler Regulatory Watch Jill Wechsler Data Integrity Key to GMP Compliance
Sean Milmo European Regulatory WatchSean MilmoExtending the Scope of Pharmacovigilance Comes at a Price
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes
Source: ePT--the Electronic Newsletter of Pharmaceutical Technology,
Click here